National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cerliponase alfa (Brineura®) is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

NCPE Assessment Process Ongoing
Rapid review commissioned 11/10/2017
Rapid review completed 27/11/2017
Rapid Review Outcome A full pharmacoeconomic evaluation is recommended.
HTA commissioned by the HSE 29/11/2017
Pre-submission consultation with Applicant 13/03/2018
Submission received from Applicant 02/08/2018
Preliminary review sent to Applicant 30/11/2018
NCPE assessment re-commenced 25/01/2019
Factual accuracy sent to Applicant 25/02/2019
NCPE assessment re-commenced 08/03/2019
NCPE assessment completed 25/03/2019
NCPE assessessment outcome The NCPE recommends that cerliponase alfa (Brineura®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary